Please Wait...

Analytical Performance Characteristics of a Prototype Immunoassay for Quantification of Alpha-Synuclein in Human Cerebrospinal Fluid

Emeric Chassaing, BS1, Philippe Vergnaud, MSc1, Tanja Schubert, PhD1, Hugo Marcel Vanderstichele, PhD2, Erik Stoops, Eng2 and Mélanie Bodnar-Wachtel, PhD1, (1)Bioclinica Lab, Lyon, France, (2)ADx NeuroSciences, Gent, Belgium

 

BACKGROUND

α-Synuclein is a pre-synaptic protein whose abnormal aggregation is the main characteristic of a sub-group of neurodegenerative disorders called α-synucleinopathies, including but not limited to Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). CFS α-Synuclein levels reflect the presence of Lewy bodies in the brain and have been shown to be decreased in PD and DLB patients as compared to healthy aging controls. Robust assays with good lot-to-lot consistency are required for integration into clinical trials. This study documents the analytical performance characteristics of a novel colorimetric ELISA targeting α-Synuclein in biological fluids, with a focus on cerebrospinal fluid (CSF).

METHODS

α-Synuclein concentrations have been determined using a colorimetric ELISA designed and developed by ADx NeuroSciences using two monoclonal antibodies. The assay was qualified for CSF, but can be modified for application for EDTA-plasma samples. After having performed familiarization runs and some adaptation of the test procedures to the needs of a service provider, the assay was challenged internally for its analytical performance characteristics such as precision, parallelism, spike-recovery, working range, sample stability, and interference using commercially available CSF samples (n=40).

RESULTS

α-Synuclein is measured in undiluted CSF and 10-50-fold diluted EDTA-plasma using a 3-hour incubation period for the samples. The new assay format specifically quantifies α-Synuclein in the absence of matrix interference as verified after dilution in α-Synuclein low CSF. Spike/recovery testing revealed good recovery rates (93 % ± 7 %). Our internal precision experiments with CSF resulted in an intra- and inter-assay variability (% CV) below 12 % and 11 %, respectively. The working range is confirmed between 90 pg/mL (Lower Limit of Quantitation) to 6142 pg/mL (Upper Limit of Quantitation). The stability of CSF α-Synuclein was assessed with respect to freeze/thawing and short-term stability at room temperature. No major difference with the reference condition was observed.

CONCLUSIONS

The newly developed α-Synuclein colorimetric ELISA assay meets all of our internal acceptance criteria for clinical trial sample testing and represents an additional tool for patient enrichment in clinical trials or treatment follow-up.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Clinical #datamanagement is essential to ensure high-quality data in #clinicaltrials, but the components are comple… https://t.co/klK81O6YA2
Bioclinica (16 hours ago)
Congratulations to Jeff Heilbraun, M.S., VP, Medical & Scientific Affairs, for his latest article on cardiovascular… https://t.co/JSuEaeQOYh
Bioclinica (5 days ago)
Changes are a fact of life - and of #clinicaltrial design. But planning and budgeting for your trial don’t have to… https://t.co/wsfMPAwLxR
Bioclinica (3 weeks ago)
Don't compromise with manual systems and spreadsheets. As an entry-level system with phased implementation, Bioclin… https://t.co/dYDJO4Qh7S
Bioclinica (3 weeks ago)
Our webinar on Neuroimaging in Parkinson’s Disease is tomorrow at 10:30 a.m. EDT. Register at:… https://t.co/4j0FGeXG0B
Bioclinica (3 weeks ago)
Today is World Ovarian Cancer Day. Ovarian cancer has the lowest survival rate of all female cancers. #Bioclinica p… https://t.co/1nMGahTMaz
Bioclinica (4 weeks ago)